Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON FORTE versus MELLARIL S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON FORTE versus MELLARIL S.
ETRAFON-FORTE vs MELLARIL-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON-FORTE is a combination of perphenazine (a phenothiazine antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system. Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Additionally, amitriptyline blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
Thioridazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, also exhibiting alpha-adrenergic blockade and anticholinergic effects.
ETRAFON-FORTE (perphenazine 4 mg / amitriptyline 25 mg) oral tablets: 1 tablet three times daily or 1 tablet four times daily. Maximum daily dose: 4 tablets (perphenazine 16 mg / amitriptyline 100 mg).
Initial 50-100 mg orally 3 times daily, titrate to 200-600 mg/day in divided doses; maximum 800 mg/day for severe psychosis.
None Documented
None Documented
Terminal elimination half-life of perphenazine: 8-12 hours; amitriptyline: 13-36 hours (mean ~20 hours). Steady-state achieved in 3-7 days. Clinical context: twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life: 10–20 hours (mean ~15 hours). Clinical context: Steady-state achieved within 4–5 days; allows once-daily or twice-daily dosing.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged). Biliary/fecal elimination accounts for about 15-20% due to enterohepatic recirculation of metabolites.
Primarily renal (approximately 70%) as metabolites (sulfoxides and glucuronides); about 30% excreted in feces via bile. Less than 1% excreted unchanged.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic